The evolution of combination immunotherapy: current successes & future goals
Immuno-Oncology Insights 2022; 3(5), 277–283
DOI: 10.18609/ioi.2022.025
Published: 20 May 2022
Interview
Roisin McGuigan, Editor, Immuno-Oncology Insights, speaks to Roy D Baynes, Senior Vice President, Clinical Research, Merck Research Laboratories
Back in 2020, Immuno-Oncology Insights spoke with Roy Baynes to discuss the rapidly developing I-O combination therapy picture – 2 years on, we caught up with him again to see how this picture has changed.